Nguyen Vien X, Nguyen Cuong C, Nguyen Ba D
Department of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
JOP. 2011 Nov 9;12(6):557-66.
Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it has a great impact on the field of oncology. Comparing to other conventional scanners, only PET/CT is capable of providing important information on accurate detecting, staging/restaging, and post-therapeutic monitoring of many cancers. Many studies have demonstrated that PET/CT changes the management in approximately 30% of all cancer patients. Because 2-((18)F)-fluoro-2-deoxy-D-glucose (FDG) is a nonspecific tracer, understanding the PET/CT limitations and pitfalls for various pancreatic conditions can lead to more accurate interpretation of PET/CT images, which ultimately would impact patient care. As a result, it is important for radiologists and other clinicians to familiarize themselves with a wide spectrum of pancreatic PET/CT findings simulating cancer from benign entities.
自从引入集成正电子发射断层扫描-计算机断层扫描（PET/CT）以来，它对肿瘤学领域产生了巨大影响。与其他传统扫描仪相比，只有PET/CT能够提供有关许多癌症的准确检测、分期/再分期以及治疗后监测的重要信息。许多研究表明，PET/CT改变了约30%的所有癌症患者的治疗管理。由于2-（18F）-氟-2-脱氧-D-葡萄糖（FDG）是一种非特异性示踪剂，了解PET/CT在各种胰腺疾病中的局限性和陷阱可以更准确地解读PET/CT图像，这最终会影响患者护理。因此，放射科医生和其他临床医生熟悉一系列模拟癌症的良性实体的胰腺PET/CT表现非常重要。
